Robert Wessman, executive chairman of Alvogen, said: “We see great opportunities for our business in Eastern Europe, and the creation of Alvogen Romania is integral to our development strategy. Through registration of our own products, portfolio acquisitions and strategic partnerships, we aim to build a strong presence in the market with a targeted product offering.”
Alvogen Romania will be led by Laurentiu Scheusan, a recognized expert in the Romanian pharmaceutical market, who formerly managed local operations for generic pharmaceuticals company, Actavis. In his role as managing director of Alvogen Romania, Mr. Scheusan will lead more than 60 new employees who have measurable experience within the local pharmaceutical industry.
Doug Drysdale, chief executive officer of Alvogen, said: “Within the next five years we aim to be one of the leading pharmaceutical companies in Romania, based upon our reputation of high quality products and services. It is our vision to set a new standard for the generic pharmaceutical business, enhance the quality of life for patients and deliver exceptional value to our customers.”